Skip to main content

Drug Interactions between cefiderocol and iptacopan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cefiderocol iptacopan

Applies to: cefiderocol and iptacopan

MONITOR: Coadministration with inducers of CYP450 2C8 (e.g., rifampin) may decrease iptacopan plasma concentrations and may result in a loss of efficacy. The proposed mechanism is induction of CYP450 2C8-mediated metabolism of iptacopan, which is primarily metabolized by the isoenzyme. However, data evaluating the interaction are not available.

MANAGEMENT: The potential for diminished pharmacologic effects of iptacopan should be considered during coadministration with CYP450 2C8 inducers. The manufacturer recommends the pharmacologic effects of iptacopan should be monitored more closely, and the CYP450 2C8 inducer be discontinued if loss of therapeutic efficacy occurs. Additionally, the pharmacologic response to iptacopan should be monitored more closely whenever a CYP450 2C8 inducer is added to or withdrawn from therapy.

References

  1. (2023) "Product Information. Fabhalta (iptacopan)." Novartis Pharmaceuticals

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer